IR BioSciences Holdings, Inc., owner of
biotechnology research and development company ImmuneRegen BioSciences, Inc., announced it has established a research entity in
Singapore and has created IMM BioSciences Asia, Ltd. IR BioSciences Holdings, Inc. will license the use of its proprietary compound Homspera through this new entity for studies on the compound's efficacy in potentially treating adverse effects of cancer, cigarette smoking, influenza, SARS/Avian Flu, HIV among others.
The future studies are expected to be held at research labs located at Biopolis, a center for biomedical sciences located in close proximity to the National University of Singapore, University Hospital and the Singapore Science Parks. The campus currently houses many mid-size and large biotech companies, as well as several key government agencies, publicly funded research institutes and R&D labs.
"We chose this facility very carefully," explains Michael K. Wilhelm, CEO of ImmuneRegen BioSciences, Inc. "This facility mirrored our needs and corporate direction. The overall design encourages strategic assistance and fosters a collaborative culture among the private and public research community, which is key in any research study. We are currently working on securing the space and should be moving ahead with our studies shortly."